Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Wyeth, Progenics To Develop Methylnaltrexone Franchise

Jun 06 2006

• By Jonathan Block

Related Content

Wyeth Gains Phase III Candidate For Treatment Of Opioid Side Effects From Progenics

Dec 23 2005

Wyeth/Progenics Shoot For Early 2007 Methylnaltrexone NDA Submission

Apr 21 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window